These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 27086681)

  • 41. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.
    Koren MJ; Lundqvist P; Bolognese M; Neutel JM; Monsalvo ML; Yang J; Kim JB; Scott R; Wasserman SM; Bays H;
    J Am Coll Cardiol; 2014 Jun; 63(23):2531-2540. PubMed ID: 24691094
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
    Kereiakes DJ; Robinson JG; Cannon CP; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM
    Am Heart J; 2015 Jun; 169(6):906-915.e13. PubMed ID: 26027630
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [PCSK9 inhibitors: What place in the management of dyslipidemia?].
    Sabouret P; Farnier M; Puymirat E
    Presse Med; 2019 Mar; 48(3 Pt 1):227-237. PubMed ID: 30853281
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels.
    Groves C; Shetty C; Strange RC; Waldron J; Ramachandran S
    Postgrad Med J; 2017 Apr; 93(1098):205-208. PubMed ID: 27531965
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.
    El Khoury P; Elbitar S; Ghaleb Y; Khalil YA; Varret M; Boileau C; Abifadel M
    Curr Atheroscler Rep; 2017 Oct; 19(12):49. PubMed ID: 29038906
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M
    Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
    Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience.
    Galema-Boers AMH; Lenzen MJ; Sijbrands EJ; Roeters van Lennep JE
    J Clin Lipidol; 2017; 11(3):674-681. PubMed ID: 28506389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia.
    Whayne TF
    Am J Cardiovasc Drugs; 2016 Apr; 16(2):83-92. PubMed ID: 26596726
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [PCSK9 Inhibitors - the magic bullet for LDL cholesterol reduction?].
    Richter K; Barthel A; Bornstein SR; El-Armouche A; Wagner M
    Dtsch Med Wochenschr; 2016 Jun; 141(12):863-9. PubMed ID: 27305302
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The new lipid-lowering drugs: focus on monoclonal antibodies].
    Borghi C; Cimminiello C
    G Ital Cardiol (Rome); 2016 Apr; 17(4 Suppl 1):14S-21. PubMed ID: 27312019
    [TBL] [Abstract][Full Text] [Related]  

  • 55. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evolocumab: A Review in Hyperlipidemia.
    Keating GM
    Am J Cardiovasc Drugs; 2016 Feb; 16(1):67-78. PubMed ID: 26643308
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility.
    Raal FJ; Chilton R; Ranjith N; Rambiritch V; Leisegang RF; Ebrahim IO; Tonder AV; Shunmoogam N; Bouharati C; Musa MG; Karamchand S; Naidoo P; Blom DJ
    Endocr Metab Immune Disord Drug Targets; 2020; 20(6):840-854. PubMed ID: 32053090
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials.
    Mu G; Xiang Q; Zhou S; Liu Z; Qi L; Jiang J; Gong Y; Xie Q; Wang Z; Zhang H; Huo Y; Cui Y
    Adv Ther; 2020 Apr; 37(4):1496-1521. PubMed ID: 32108309
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
    Okere AN; Serra C
    Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.